Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

INTRODUCTION: Antiviral drugs have shown limited effectiveness in treating patients with coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 patients. METHODS: An investigator-initiated, multi...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Infect Dis Ther
मुख्य लेखकों: Bosaeed, Mohammad, Mahmoud, Ebrahim, Alharbi, Ahmad, Altayib, Hadeel, Albayat, Hawra, Alharbi, Faisal, Ghalilah, Khalid, Al Arfaj, Abdulmajid, AlJishi, Jumana, Alarfaj, Abdullatif, Alqahtani, Hajar, Almutairi, Badriah M., Almaghaslah, Manar, Alyahya, Nawaf M., Bawazir, Abdullah, AlEisa, Saud, Alsaedy, Abdulrahman, Bouchama, Abderrezak, Alharbi, Malak, AlShamrani, Majid, Al Johani, Sameera, Aljeraisy, Majed, Alzahrani, Mohammed, Althaqafi, Abdulhakeem O., Almarhabi, Hassan, Alotaibi, Athari, Alqahtani, Nasser, Arabi, Yaseen M., Aldibasi, Omar S., Alaskar, Ahmad
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer Healthcare 2021
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8316887/
https://ncbi.nlm.nih.gov/pubmed/34319552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00496-6
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन